drugset
drugset / Trial / NCT00073749

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

NCT00073749 ↗

Phase 1 Completed 79 enrolled Pfizer
Non-randomizedOpen-labelTreatment

Summary

To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).

Timeline

Start
2003-08
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Inotuzumab Ozogamicin Monoclonal antibody 1.8 mg/m2 Intravenous

Indications

B-cell non-Hodgkin lymphoma